Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, Macdonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW. Plevris N, et al. Among authors: kane c. J Gastroenterol Hepatol. 2021 Aug;36(8):2067-2075. doi: 10.1111/jgh.15390. Epub 2021 Mar 5. J Gastroenterol Hepatol. 2021. PMID: 33381875
A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.
Lerner A, Lee AJX, Yan H, Van Griethuysen J, Bartlett AD, Veli M, Jiang Y, Luong M, Naban N, Kane C, Conibear J, Papadatos-Pastos D, Ahmad T, Chao D, Anand G, Asghar US. Lerner A, et al. Among authors: kane c. Clin Oncol (R Coll Radiol). 2024 Mar;36(3):193-199. doi: 10.1016/j.clon.2024.01.009. Epub 2024 Jan 16. Clin Oncol (R Coll Radiol). 2024. PMID: 38246850
Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations.
Roberts JL, Wang LL, Rose B, Seibert TM, Madlensky L, Nielsen SM, Salmasi A, Kader AK, Kane CJ, Crawford ED, Javier-Desloges J, McKay RR, Bagrodia A. Roberts JL, et al. Among authors: kane cj. Urol Oncol. 2024 Oct 30:S1078-1439(24)00690-2. doi: 10.1016/j.urolonc.2024.10.010. Online ahead of print. Urol Oncol. 2024. PMID: 39482144
Unusual holopelagic Sargassum mass beaching in Northwest Africa: Morphotypes, chemical composition, and potential valorisation.
Bousso NC, Brehmer P, Ndiaye W, Stiger-Pouvreau V, Kane C, Gautier M, Faye M, Fricke A, Diadhiou HD, Aroui Boukbida H, Weinberger F, Ramasamy B, Diedhiou F, Diop MS, Balde BS, Simon G, Quack B. Bousso NC, et al. Among authors: kane c. Sci Total Environ. 2024 Dec 10;955:177018. doi: 10.1016/j.scitotenv.2024.177018. Epub 2024 Oct 21. Sci Total Environ. 2024. PMID: 39437924
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
Willemin ME, Gong J, Hilder BW, Masterson T, Tolbert J, Renaud T, Heuck C, Kane C, De Zwart L, Girgis S, Ma X, Ouellet D. Willemin ME, et al. Among authors: kane c. Target Oncol. 2024 Nov;19(6):965-979. doi: 10.1007/s11523-024-01093-6. Epub 2024 Sep 16. Target Oncol. 2024. PMID: 39285155 Free PMC article. Clinical Trial.
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Ye JC, Biran N, Nair S, Lin X, Qi K, Londhe A, Ammann E, Renaud T, Kane C, Parekh T, Gray K, Peterson S, Costa LJ. Ye JC, et al. Among authors: kane c. Clin Lymphoma Myeloma Leuk. 2024 Aug 13:S2152-2650(24)00295-7. doi: 10.1016/j.clml.2024.08.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39271448
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study.
Deivasigamani S, Adams ES, Stock S, Kotamarti S, Séguier D, Taha T, Howard LE, Aminsharifi A, Jibara G, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Guerrios-Rivera L, Freedland SJ, Polascik TJ. Deivasigamani S, et al. Among authors: kane cj. Prostate Cancer Prostatic Dis. 2024 Aug 12. doi: 10.1038/s41391-024-00880-6. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39134653
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, Lipe B, Qin X, Campagna M, Masterson T, Tomlinson C, Hilder B, Tolbert J, Renaud T, Smit MD, Gray K, Kane C, Heuck C, van de Donk NWCJ. Chari A, et al. Among authors: kane c. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):665-693.e14. doi: 10.1016/j.clml.2024.05.003. Epub 2024 May 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38871558 Free article. Clinical Trial.
995 results